These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2897209)

  • 1. Activation of guanylate cyclase and inhibition of platelet aggregation by endothelium-derived relaxing factor released from cultured cells.
    Hawkins DJ; Meyrick BO; Murray JJ
    Biochim Biophys Acta; 1988 May; 969(3):289-96. PubMed ID: 2897209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets.
    Alheid U; Frölich JC; Förstermann U
    Thromb Res; 1987 Sep; 47(5):561-71. PubMed ID: 3499684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelium-derived relaxant factor inhibits platelet activation.
    Busse R; Lückhoff A; Bassenge E
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):566-71. PubMed ID: 2830546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelium-derived relaxing factor and atriopeptin II elevate cyclic GMP levels in pig aortic endothelial cells.
    Martin W; White DG; Henderson AH
    Br J Pharmacol; 1988 Jan; 93(1):229-39. PubMed ID: 2894877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets.
    Radomski MW; Palmer RM; Moncada S
    Br J Pharmacol; 1987 Sep; 92(1):181-7. PubMed ID: 3311265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical.
    Ignarro LJ; Byrns RE; Buga GM; Wood KS
    Circ Res; 1987 Dec; 61(6):866-79. PubMed ID: 2890446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid.
    Ignarro LJ; Harbison RG; Wood KS; Kadowitz PJ
    J Pharmacol Exp Ther; 1986 Jun; 237(3):893-900. PubMed ID: 2872327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
    Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
    Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous measurement of endothelium-derived relaxing factor by bioassay and guanylate cyclase stimulation.
    Kondo K; Mitchell JA; de Nucci G; Vane JR
    Br J Pharmacol; 1989 Oct; 98(2):630-6. PubMed ID: 2573403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation.
    Furlong B; Henderson AH; Lewis MJ; Smith JA
    Br J Pharmacol; 1987 Apr; 90(4):687-92. PubMed ID: 3495310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation.
    Mülsch A; Lückhoff A; Pohl U; Busse R; Bassenge E
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):119-25. PubMed ID: 2552329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP.
    Alheid U; Reichwehr I; Förstermann U
    Eur J Pharmacol; 1989 May; 164(1):103-10. PubMed ID: 2546782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
    Homer KL; Wanstall JC
    Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin.
    Macdonald PS; Read MA; Dusting GJ
    Thromb Res; 1988 Mar; 49(5):437-49. PubMed ID: 3287674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelium-derived relaxing factor (EDRF): a defence mechanism against platelet aggregation and vasospasm in human coronary arteries.
    Förstermann U; Mügge A; Alheid U; Bode SM; Frölich JC
    Eur Heart J; 1989 Nov; 10 Suppl F():36-43. PubMed ID: 2620689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical tolerance to nitroglycerin is due to impaired biotransformation of nitroglycerin and biological counterregulation, not to desensitization of guanylate cyclase.
    Mülsch A; Busse R; Bassenge E
    Z Kardiol; 1989; 78 Suppl 2():22-5; discussion 64-7. PubMed ID: 2573982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of methylmercury (CH3HgCl) on the production of endothelium-derived relaxing factor (EDRF) by cultured human umbilical vascular endothelial cells based on its anti-aggregatory effect on human platelets.
    Ohno M; Kishimoto T; Tada M
    Cell Biol Toxicol; 1995 Dec; 11(6):303-11. PubMed ID: 8788207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of endothelium-derived relaxing factor in porcine kidney epithelial LLC-PK1 cells: an intra- and intercellular messenger for activation of soluble guanylate cyclase.
    Ishii K; Chang B; Kerwin JF; Wagenaar FL; Huang ZJ; Murad F
    J Pharmacol Exp Ther; 1991 Jan; 256(1):38-43. PubMed ID: 1671098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelium-dependent potentiation of human platelet aggregation.
    Loeb AL; Peach MJ; Gear AR
    Thromb Res; 1989 Jun; 54(5):477-86. PubMed ID: 2505402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide from vascular smooth muscle cells: regulation of platelet reactivity and smooth muscle cell guanylate cyclase.
    Mollace V; Salvemini D; Anggard E; Vane J
    Br J Pharmacol; 1991 Nov; 104(3):633-8. PubMed ID: 1724627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.